Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naproxen sodium/metoclopramide - POZEN

Drug Profile

Naproxen sodium/metoclopramide - POZEN

Alternative Names: Metoclopramide/naproxen-sodium; MT 100; Naproxen-sodium/metoclopramide

Latest Information Update: 30 Nov 2005

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator POZEN
  • Class Aminobenzoic acids; Antiemetics; Antimigraines; Antipyretics; Benzamides; Chlorobenzenes; Diethylamines; Gastrokinetics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Phenyl ethers; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Dopamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Migraine

Most Recent Events

  • 28 Nov 2005 Registered for Migraine in United Kingdom (PO)
  • 05 Aug 2005 Withdrawn - Preregistration for Migraine in USA (PO)
  • 03 Mar 2005 A Committee on Safety of Medicines to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom agreed to advise the MHRA that the MAA be granted for naproxen sodium/metoclopramide
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top